Celia Eckert Sells 1,767 Shares of Xencor (NASDAQ:XNCR) Stock

Xencor, Inc. (NASDAQ:XNCR) SVP Celia Eckert sold 1,767 shares of the stock in a transaction on Friday, March 6th. The shares were sold at an average price of $11.02, for a total value of $19,472.34. Following the completion of the transaction, the senior vice president owned 76,918 shares of the company’s stock, valued at $847,636.36. The trade was a 2.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Celia Eckert also recently made the following trade(s):

• On Thursday, March 5th, Celia Eckert sold 3,244 shares of Xencor stock. The shares were sold at an average price of $11.25, for a total value of $36,495.00.
• On Tuesday, March 3rd, Celia Eckert sold 1,492 shares of Xencor stock. The shares were sold at an average price of $11.90, for a total value of $17,754.80.

Xencor Stock Performance

NASDAQ:XNCR opened at $11.98 on Wednesday. The stock has a market cap of $878.61 million, a P/E ratio of -9.66 and a beta of 0.95. The company has a current ratio of 6.25, a quick ratio of 6.25 and a debt-to-equity ratio of 0.12. The stock’s 50-day moving average is $12.67 and its 200-day moving average is $13.06. Xencor, Inc. has a 1-year low of $6.92 and a 1-year high of $18.69.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.55. Xencor had a negative net margin of 73.20% and a negative return on equity of 14.58%. The business had revenue of $28.24 million during the quarter, compared to analyst estimates of $29.97 million. During the same quarter last year, the business earned ($0.62) EPS. The firm’s quarterly revenue was down 46.6% on a year-over-year basis. Equities research analysts anticipate that Xencor, Inc. will post -3.68 earnings per share for the current year.

Trending Headlines about Xencor

Here are the key news stories impacting Xencor this week:

• Positive Sentiment: Xencor reported an earnings beat on Feb. 25 (EPS -$0.09 vs. consensus -$0.64), which can support sentiment despite revenue weakness; investors often reward upside to EPS expectations. Earnings Summary
• Positive Sentiment: Analyst coverage includes new/raised targets (Truist coverage with a Buy, Barclays raising its target to $27), which provides external validation and upside to the consensus price target (~$25). Analyst Notes
• Neutral Sentiment: Institutional holders show modest position changes (small increases by several funds); these are routine rebalances and not a clear directional signal. Institutional Activity
• Negative Sentiment: Xencor and Genentech agreed to end their protein-therapeutics collaboration — this removes a strategic partner that could have provided development resources, milestones or royalties; termination may return rights to Xencor but creates near-term uncertainty for the affected programs and potential revenue. Xencor, Genentech to End Protein Therapeutics Collaboration
• Negative Sentiment: Clustered insider selling by senior executives was disclosed this week: CEO Bassil Dahiyat sold ~21,476 shares across Mar 5–6, SVP Celia Eckert sold ~5,011 shares, and VP John Desjarlais sold ~6,620 shares (transactions at ~$11–$11.90 per share). While each sale reduces insider holdings only a few percent, the timing and concentration can be read negatively absent a disclosed 10b5‑1 plan. Relevant filings: CEO Form 4(s) SVP Form 4(s) VP Form 4(s)

Hedge Funds Weigh In On Xencor

Institutional investors and hedge funds have recently made changes to their positions in the stock. Hantz Financial Services Inc. grew its stake in shares of Xencor by 209.1% in the 3rd quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 2,156 shares during the period. GAMMA Investing LLC raised its stake in Xencor by 77.1% during the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 1,449 shares during the period. Farther Finance Advisors LLC acquired a new position in Xencor during the 3rd quarter worth approximately $44,000. Federated Hermes Inc. boosted its holdings in Xencor by 114.3% in the third quarter. Federated Hermes Inc. now owns 3,947 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 2,105 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its holdings in Xencor by 85.5% in the third quarter. Nisa Investment Advisors LLC now owns 5,260 shares of the biopharmaceutical company’s stock worth $62,000 after acquiring an additional 2,424 shares in the last quarter.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Barclays raised their price target on shares of Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a research note on Thursday, February 26th. Truist Financial started coverage on Xencor in a report on Monday, November 24th. They issued a “buy” rating and a $29.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xencor in a research report on Monday, December 29th. Finally, Wall Street Zen downgraded Xencor from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.00.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.